250 related articles for article (PubMed ID: 35769464)
1. A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma.
Luo C; Wang S; Shan W; Liao W; Zhang S; Wang Y; Xin Q; Yang T; Hu S; Xie W; Xu N; Zhang Y
Front Immunol; 2022; 13():909189. PubMed ID: 35769464
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Potential of METTL7B in Glioma.
Fu R; Luo X; Ding Y; Guo S
Neuroimmunomodulation; 2022; 29(3):186-201. PubMed ID: 35034026
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.
Mei J; Cai Y; Xu R; Yang X; Zhou W; Wang H; Liu C
Technol Cancer Res Treat; 2021; 20():15330338211011970. PubMed ID: 33955303
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
5. Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
Li J; Guo Q; Xing R
BMC Cancer; 2023 Aug; 23(1):727. PubMed ID: 37543576
[TBL] [Abstract][Full Text] [Related]
6. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
Front Genet; 2022; 13():1053263. PubMed ID: 36712869
[No Abstract] [Full Text] [Related]
7. Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.
Xu S; Wang Z; Ye J; Mei S; Zhang J
Front Oncol; 2021; 11():729103. PubMed ID: 34568059
[TBL] [Abstract][Full Text] [Related]
8. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation.
Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y
Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044
[TBL] [Abstract][Full Text] [Related]
9. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
12. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
13. Integrated machine learning methods identify FNDC3B as a potential prognostic biomarker and correlated with immune infiltrates in glioma.
Wang X; Huang Y; Li S; Zhang H
Front Immunol; 2022; 13():1027154. PubMed ID: 36275754
[TBL] [Abstract][Full Text] [Related]
14. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
[TBL] [Abstract][Full Text] [Related]
15. A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.
Zeng Z; Hu C; Ruan W; Zhang J; Lei S; Yang Y; Peng P; Pan F; Chen T
Front Immunol; 2022; 13():1001381. PubMed ID: 36159801
[TBL] [Abstract][Full Text] [Related]
16. A risk signature of four aging-related genes has clinical prognostic value and is associated with a tumor immune microenvironment in glioma.
Luo H; Tao C; Long X; Huang K; Zhu X
Aging (Albany NY); 2021 Jun; 13(12):16198-16218. PubMed ID: 34114970
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
[No Abstract] [Full Text] [Related]
18. Establishment and Validation of a 5 m6A RNA Methylation Regulatory Gene Prognostic Model in Low-Grade Glioma.
Bai Z; Wang X; Zhang Z
Front Genet; 2022; 13():655169. PubMed ID: 35281815
[No Abstract] [Full Text] [Related]
19. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Zhang Q; Hong J
Front Genet; 2020; 11():363. PubMed ID: 32351547
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]